Inhibition-suppression of physiological lactation

Indication for Cabergoline

Population group: Suitable for women, only adults (18 - 65 years old)

Cabergoline is indicated for the inhibition of physiological lactation soon after delivery and for suppression of already established lactation:

  1. After parturition, when the mother elects not to breast feed the infant or when breast feeding is contraindicated due to medical reasons related to the mother or the new-born.
  2. After stillbirth or abortion.

Cabergoline prevents/suppresses physiological lactation by inhibiting prolactin secretion.

In controlled clinical trials, cabergoline given as a single 1 mg administration during the first day post-partum, was effective in inhibiting milk secretion, as well as breast engorgement and pain in 70-90% of the women. Less than 5% of women experienced rebound breast symptomatology during the third post-partum week (which was usually mild in severity).

Suppression of milk secretion and relief of breast engorgement and pain are obtained in approximately 85% of nursing women treated with a total dose of 1 mg cabergoline given in four divided doses over two days. Rebound breast symptomatology after day 10 is uncommon (approximately 2% of cases).

For this indication, competent medicine agencies globally authorize below treatments:

0.5-1 mg in 2 divided doses

Route of admnistration

Oral

Defined daily dose

0.5 - 1 mg

Dosage regimen

From 0.25 To 0.5 mg 2 time(s) per day every day

Detailed description

For inhibition of lactation cabergoline should be administered during the first day post-partum. The recommended therapeutic dose is 1 mg (two 0.5 mg tablets) given as a single dose.

For suppression of established lactation the recommended therapeutic dosage regimen is 0.25 mg (one-half 0.5 mg tablet) every 12 hours for two days (1 mg total dose). This dosage regimen has been demonstrated to be better tolerated than the single dose regimen in women electing to suppress lactation having a lower incidence of adverse events, in particular of hypotensive symptoms.

Active ingredient

Cabergoline is a dopaminergic ergoline derivative endowed with a potent and long-lasting PRL-lowering activity.

Read more about Cabergoline

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner